Innovations + Investments in Healthcare Summit 2015

Novartis

NovartisNovartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. In 2009, the Group's continuing operations achieved net sales of USD 44.3 billion, while approximately USD 7.5 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 102,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.

Novartis RSS Channel

Title Filter      Display #  
# Article Title
1 Novartis announces global partnership with Amgen to develop and commercialize pioneering neuroscience treatments
2 Novartis acquires all remaining rights to GSK's Ofatumumab to develop treatments for MS and other autoimmune indications
3 Novartis malaria treatment Coartem® 80/480mg receives WHO prequalification, enabling greater access for patients
4 Novartis Pharmaceuticals launches the first app for visually impaired people for use with the Apple Watch and other smart watches
5 Novartis deepens its industry leading pipeline with acquisition of Spinifex Pharmaceuticals, Inc.
6 Novartis highlights strong innovation momentum at its second Meet Novartis Management investor day
7 Combination of Novartis drugs Tafinlar® and Mekinist® shows significant survival benefit in patients with metastatic melanoma
8 Novartis drug Afinitor® extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumors
9 Novartis accelerates cancer immunotherapy efforts with Aduro Biotech alliance and launch of new immuno-oncology research group
10 FDA approves first biosimilar ZarxioTM (filgrastim-sndz) from Sandoz
11 Novartis announces completion of transactions with GSK
12 Novartis receives FDA approval of Farydak®, the first HDAC inhibitor for patients with multiple myeloma
13 Novartis Pharmaceuticals announces a joint investment company with Qualcomm
14 Novartis collaborates with Intellia Therapeutics and Caribou Biosciences
15 Novartis Foundation symposium showcases sustainable healthcare interventions
16 New data on the global economic impact and burden of preventable blindness and vision impairment
17 Novartis announces clinical collaboration to evaluate Bristol-Myers Squibb's novel immunotherapy in combination treatments for NSCLC
18 Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial
19 Novartis provides drug candidate compounds to TB Alliance
20 Novartis maintained strong innovation momentum in second quarter
World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]